A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors.
- DOI
- 10.1007/s10147-026-03103-1
- Published
- 2026 Sep
- Container
- International journal of clinical oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10147-026-03103-1,
title = {A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors.},
author = {Yamamoto N and Bajaj G and Adams HC 3rd and Takahashi A and Fukushi R and Forssmann U and Ramirez Ganoza E and Kuboki Y},
year = {2026},
journal = {International journal of clinical oncology},
doi = {10.1007/s10147-026-03103-1},
url = {https://doi.org/10.1007/s10147-026-03103-1}
}RIS
TY - JOUR TI - A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors. AU - Yamamoto N AU - Bajaj G AU - Adams HC 3rd AU - Takahashi A AU - Fukushi R AU - Forssmann U AU - Ramirez Ganoza E AU - Kuboki Y PY - 2026 JO - International journal of clinical oncology DO - 10.1007/s10147-026-03103-1 UR - https://doi.org/10.1007/s10147-026-03103-1 ER -
APA
N, Y., G, B., 3rd, A. H., A, T., R, F., U, F., E, R. G., & Y, K. (2026). A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors.. International journal of clinical oncology. https://doi.org/10.1007/s10147-026-03103-1
Source records
- pubmed · retrieved 2026-09-25T19:39:54.401Z